Pursuant to Regulation 30 the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, NGL Fine-Chem has informed that the Company has received Certificate of suitability No. CEP 2022-160 - Rev 00, from European Directorate for the Quality of Medicines & Healthcare (EDQM) for its product FLUNIXIN MEGLUMINE. This certificate facilitates registration and use of FLUNIXIN MEGLUMINE manufactured by the company by the European customers for their finished product.
The above information is a part of company’s filings submitted to BSE.
